ArticleOncotarget2021

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.

Hélène Marijon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.